Anti-Human IL5 Recombinant Antibody (TAB-031)

Customer Review

There are currently no Customer reviews or questions for TAB-031. Click the button above to contact us or submit your feedback about this product.

Jessica Green
18.Jun,23

Excellent for IL5 Research

The Anti-Human IL5 Therapeutic Antibody (Bosatria) has been excellent for our IL5 studies. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

Michael Evans
23.Nov,22

Effective in Immunoassays

We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for IL5 is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Sarah Davis
12.May,21

Consistent and Reliable

This antibody has proven to be consistent and reliable in our assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for IL5 have been particularly beneficial.

Q&As

1. Is the anti-Human IL5 therapeutic antibody Bosatria suitable for use in Western blotting?

   A: Yes, the anti-Human IL5 therapeutic antibody Bosatria (TAB-031) is suitable for use in Western blotting. It provides specific binding to IL5, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-Human IL5 therapeutic antibody Bosatria?

   A: The recommended storage condition for the anti-Human IL5 therapeutic antibody Bosatria (TAB-031) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-Human IL5 therapeutic antibody Bosatria be used in immunoprecipitation assays?

   A: Yes, the anti-Human IL5 therapeutic antibody Bosatria (TAB-031) can be used in immunoprecipitation assays. It provides specific binding to IL5, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-Human IL5 therapeutic antibody Bosatria effective in ELISA applications?

   A: Yes, the anti-Human IL5 therapeutic antibody Bosatria (TAB-031) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of IL5.

5. What is the optimal dilution for using the anti-Human IL5 therapeutic antibody Bosatria in immunofluorescence?

   A: The optimal dilution for using the anti-Human IL5 therapeutic antibody Bosatria (TAB-031) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Calzetta, Luigino, et al. "Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab." British Journal of Pharmacology 177.20 (2020): 4750-4765. https://doi.org/10.1111/bph.15240
   This study investigates the effectiveness of targeting the IL-5 pathway in addressing airway hyperresponsiveness (AHR) in asthma by comparing two monoclonal antibodies, benralizumab and mepolizumab. The research focuses on their ability to modulate AHR in human airways passively sensitized to mimic asthmatic conditions. The study measures the inhibition of AHR to histamine, parasympathetic activation, and mechanical stress, as well as the modulation of cyclic AMP (cAMP) levels. The results demonstrate that both benralizumab and mepolizumab significantly reduce AHR, with benralizumab being more potent. The study concludes that targeting the IL-5/IL-5Rα axis is an effective strategy for preventing AHR.
   Creative Biolabs provided the benralizumab (Cat# TAB-222) and mepolizumab (Cat# TAB-031) used in this study. These antibodies were essential for the comparative analysis of their effects on AHR and cAMP levels in human bronchial tissues. The use of these reagents allowed the researchers to determine the differential potency and efficacy of benralizumab and mepolizumab in modulating AHR, thus contributing significantly to the understanding of their therapeutic potential in treating asthma.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-031, RRID: AB_3111765)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Mepolizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Mepolizumab.

Related Diseases

Asthma

Inflammatory Bowel Diseases

Autoimmune Thyroid Disease

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "IL5"

Select a product category from the dropdown menu below to view related products.